Study Of 323U66 SR In Major Depressive Disorder
NCT00135512 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 234
Last updated 2019-02-01
Summary
This study was designed to evaluate the efficacy and safety in major depressive disorder patients.
Conditions
- Depressive Disorder
Interventions
- DRUG
-
bupropion hydrochloride
Study drug
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
GSK Clinical Trials · GlaxoSmithKline
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 64 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2004-12-01
- Primary Completion
- 2007-05-28
- Completion
- 2007-05-28
Countries
- Japan
Study Locations
More Related Trials
-
Oral Fluency and the Response to Antidepressant Therapy in the Elderly With a Unipolar Depressive Episode
NCT03227133 ·Status: UNKNOWN ·Phase: NA
-
Safety, Tolerability and Efficacy of the Transdermal System in Elderly Subjects With Major Depression
NCT00285766 ·Status: COMPLETED ·Phase: PHASE3
-
A Multicenter Clinical Study on Shuganjieyu Capsule Combined With Fluoxetine in the Treatment of Depression
NCT05361330 ·Status: UNKNOWN ·Phase: NA
-
Early Prediction of Fluoxetine Response
NCT01075529 ·Status: COMPLETED ·Phase: PHASE4
-
Standardized Assessment in Depression Treatment in Routine Psychiatric Services
NCT06332261 ·Status: COMPLETED
-
Antidepressant Medication Plus Directly Observed Therapy for Improving Adherence to Antiretroviral Therapy
NCT00338767 ·Status: COMPLETED ·Phase: PHASE2
-
Study Protocol for a Smartphone Application-based Intervention for Subthreshold Depression
NCT04136041 ·Status: COMPLETED ·Phase: NA
-
Neuroimaging MAO-B in Medication Free TR-MDD Using Novel Tracer
NCT02153281 ·Status: COMPLETED ·Phase: NA
-
Characterizing Dopamine Receptor Binding in Treatment Resistant Depression
NCT03537794 ·Status: RECRUITING
-
Paroxetine/Bupropion in Depression With Suicide Attempt or Thoughts: fMRI Study
NCT01748955 ·Status: COMPLETED ·Phase: PHASE4
-
RCT of Brain Longitudinal Biomarker Study (OPT-Neuro RCT)
NCT05531591 ·Status: COMPLETED ·Phase: PHASE4
-
Clinical and Neurobiological Profile Predictive of Pejorative Outcome of Depression
NCT03690856 ·Status: UNKNOWN ·Phase: NA
-
Smartphone Intervention for Subthreshold Depression
NCT03110016 ·Status: COMPLETED ·Phase: NA
-
A Study of Diagnosis and Treatment of Depression Based on Biological Evidence of Dopamine Reward Pathway
NCT03148509 ·Status: UNKNOWN ·Phase: PHASE4
-
Glabellar Botulinum Toxin Injections for the Treatment of Geriatric Depression
NCT03833063 ·Status: WITHDRAWN ·Phase: PHASE1
-
PET Imaging Using the Tracer [18F]VAT to Assess the Antidepressant Effect of Nicotine.
NCT07095205 ·Status: RECRUITING ·Phase: PHASE4
-
Deep Phenotyping for Clinical Inferring Response in Treatment Resistant Depression
NCT06396312 ·Status: RECRUITING
-
The Antidepressant Advisor (Study 3): fMRI Study to Predict Treatment Response in Patients With Depression
NCT04342299 ·Status: COMPLETED
-
Modafinil's Effects on Cognition in Remitted MDD
NCT03620253 ·Status: TERMINATED ·Phase: PHASE3
-
Pharmacogenetic and Antidepressant Treatment in Elderly
NCT02856477 ·Status: TERMINATED ·Phase: NA
-
Accelerated Bilateral Sequential Theta Burst Stimulation in Older Adults With Treatment-resistant Depression
NCT06323486 ·Status: RECRUITING ·Phase: NA
-
Repurposing of Dextromethorphan as an Adjunct Therapy in Patients With Major Depressive Disorder
NCT05181527 ·Status: COMPLETED ·Phase: PHASE4
-
Predicting Response to Depression Treatment (PReDicT)
NCT02790970 ·Status: COMPLETED ·Phase: NA
-
Major Depressive Disorder: Early Prediction of Non-response to Antidepressant Therapy Via a Mobile Digital Scale
NCT03872492 ·Status: TERMINATED ·Phase: NA
-
Improving Therapeutic Learning in Depression: Proof of Concept
NCT02376257 ·Status: COMPLETED ·Phase: PHASE2